European Pharmaceutical Review

OCTOBER 18, 2023

Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

Food and Drug Administration 110

Food and Drug Administration FDA Food Safety 110

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD).

Transportation 82

Transportation Consulting Safety Medicine 82

PharmaTimes

JANUARY 27, 2023

Clinical study is researching patients with diabetes and advanced chronic kidney disease

Patients 90

Patients 90

Pharmaceutical Technology

JANUARY 10, 2023

CinCor Pharma is focused on developing new treatments for chronic kidney disease and resistant and uncontrolled hypertension. It is currently in clinical development to treat hypertension and primary aldosteronism. AstraZeneca stated that the transaction would boost its cardiorenal pipeline by adding baxdrostat.

Pharma 97

Pharma Prospecting Leads Patients 97

European Pharmaceutical Review

OCTOBER 16, 2023

billion, Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences. To date, the small molecule drug has been evaluated in nine clinical trials. In a deal of up to $1.3

Medicine 59

Medicine Medical Patients Pharmaceutical 59

Clarify Health

MARCH 2, 2023

March is National Kidney Month. Each year, patient advocacy organizations, medical and nursing societies, and government agencies work to promote awareness and education about the importance of kidney health and the impact of kidney disease. Unfortunately, that number is expected to surpass one million patients by 2030.

Education 52

Education Insurance Healthcare Healthcare 52

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

Pharmacy Times

JANUARY 19, 2023

Data from a randomized clinical trial supports previous clinical findings on SGLT2 inhibitors and their ability to slow the progression of chronic kidney disease.

63

63

World of DTC Marketing

MAY 11, 2021

As the oldest millennials start to hit 40, many are finding themselves coping with chronic health conditions — more so than previous generations, according to some recent research and it’s going to lead to higher healthcare costs for ALL of us. Those with two concurrent chronic health issues spend five times as much.”

Insurance 185

Insurance Healthcare Healthcare Prescription 185

European Pharmaceutical Review

JANUARY 9, 2023

The deal also offers the possibility for baxdrostat (CIN-107) to be combined with Farxiga ( dapagliflozin ), helping to address cardiorenal diseases, where there is a high unmet medical need. In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels, across a wide range of doses.

Pharma 88

Pharma Medical Pharmaceutical Patients 88

Pharmaceutical Technology

MAY 23, 2023

The UK’s medicines and healthcare products regulatory agency (MHRA) has granted marketing authorisation for Akebia Therapeutics’ Vafseo (vadadustat) to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on chronic maintenance dialysis.

Marketing 52

Marketing Safety Medicine Healthcare 52

Pharmaceutical Technology

OCTOBER 27, 2022

Bayer has received approval from Health Canada for finerenone as an adjunct to standard-of-care treatment for chronic kidney disease (CKD) and type 2 diabetes (T2D) in adult patients. Health Canada approval is based on the positive data from the Phase III FIDELIO-DKD and FIGARO-DKD clinical trials of Kerendia.

Safety 52

Safety Patients Medical Pharmaceutical 52

Pharma Leaders

JUNE 27, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion recommending authorisation of GlaxoSmithKline’s (GSK) daprodustat for symptomatic anaemia linked to chronic kidney disease (CKD). CKD is characterised by gradual kidney function loss.

Food and Drug Administration 52

Food and Drug Administration Medicine Food Safety 52

European Pharmaceutical Review

JUNE 13, 2023

Chinook Therapeutics has two late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease. Clinical data has shown atrasentan has demonstrated significant reductions in proteinuria. IgA nephropathy IgAN is a progressive, rare kidney disease. The post £2.5b

Biopharma 52

Biopharma Safety Leads Pharmaceutical 52

European Pharmaceutical Review

MAY 8, 2023

A marketing authorisation for PRX-102 (pegunigalsidase alfa) , the first Poly(ethylene glycol) (PEG)ylated enzyme for Fabry disease, has been granted by the European Commission (EC). CHMP recommends first pegylated enzyme for Fabry disease… The PEGylated enzyme replacement therapy Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc.

Medicine 82

Medicine Patients Pharmaceutical Marketing 82

European Pharmaceutical Review

FEBRUARY 7, 2023

The first-in-class, oral, once-daily SGLT2 inhibitor has shown efficacy in preventing and delaying cardiorenal disease, while also protecting the organs, research has shown. This was the largest clinical trial to date in HF patients with LVEF above 40 percent, with 6,263 randomised patients.

Patients 85

Patients Medicine Pharmaceutical 85

Pharmaceutical Technology

JUNE 12, 2023

Novartis will buy US-based clinical-stage biopharmaceutical company Chinook Therapeutics in a $3.5bn deal. The deal is a merger of a newly formed subsidiary of the company with Chinook, which has two late-stage medicines currently under development to treat IgA nephropathy (IgAN), a rare, progressive chronic kidney disease.

Medicine 59

Medicine Healthcare Healthcare Leads 59

European Pharmaceutical Review

FEBRUARY 6, 2023

In a recent Phase II study , FT011, a novel, first-in-class oral therapy for chronic fibrosis in multiple organs showed meaningful improvements in over 60 percent of scleroderma patients after 12 weeks. This GPCR is silent in healthy tissue but activated following injury or disease.

Physicians 85

Physicians Patients Safety Pharmaceutical 85

Pharma Leaders

MAY 19, 2023

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) have announced that the US’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia (difelikefalin) to treat chronic kidney disease (CKD)-associated pruritus.

Consulting 52

Consulting Patients Medicine Pharma 52

World of DTC Marketing

MARCH 19, 2021

Under value-based care agreements, providers are rewarded for helping patients improve their health, reduce the effects and incidence of chronic disease, and live healthier lives in an evidence-based way. Also, nearly half of all Americans—133 million people—suffer from at least one ongoing or chronic health condition.

Healthcare 143

Healthcare Healthcare Side effects Medical 143

Pharmaceutical Technology

APRIL 26, 2023

Akebia Therapeutics has received marketing authorisation from the European Commission (EC) for its Vafseo (vadadustat) to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on chronic maintenance dialysis.

Marketing 52

Marketing Safety Patients 52

European Pharmaceutical Review

DECEMBER 12, 2022

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). Clinical trial data assessing dapagliflozin for chronic heart failure.

Transportation 103

Transportation Medical science Safety Patients 103

pharmaphorum

JANUARY 17, 2023

Unify, launched in December 2020, is AstraZeneca’s patient app and clinical trial support tool. Attrition in drug development for chronic disease is high, often because the wrong patients are selected for clinical trials,” Challis explained. Chronic diseases are heterogeneous and complex,” he continued.

Medicine 97

Medicine Patients Transportation Healthcare 97

pharmaphorum

SEPTEMBER 20, 2022

data from the phase 2 LILAC (Part A) clinical trial published this month shows that the experimental lupus therapy could reduce disease activity in the joints of patients, globally improving their condition. Sponsored by Biogen Inc., Litifilimab could offer a lifeline. There is currently no known cure for lupus.

Medicine 108

Medicine Leads Safety Medical 108

pharmaphorum

JANUARY 9, 2023

The $26-per-share upfront deal focuses on baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) in clinical testing for treatment-resistant hypertension and chronic kidney disease. AstraZeneca has extended its cardiorenal pipeline with a $1.3

Prospecting 52

Prospecting Pharma Patients Sales 52

Pharmaceutical Technology

MAY 2, 2023

The loan also provides capital to sustain the development of the company’s pre-clinical pipeline and will be made accessible to the company in three tranches. FibroGen will receive an initial tranche of $75m in May 2023. The second tranche of $37.5m will be provided during the third quarter of 2023.

Management 52

Management Patients 52

Pharma Leaders

APRIL 19, 2023

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response or intolerance to a phosphate binder therapy. Diarrhea was the most common side effect using Xphozah in clinical trials.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Food 52

Legacy MEDSearch

SEPTEMBER 12, 2023

LimFlow SA , a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. The LimFlow System received the CE Mark and is currently available commercially in Europe.

FDA 52

FDA Patients Food and Drug Administration Recruitment 52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Manufacturing Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Manufacturing Pharmaceutical 52

pharmaphorum

NOVEMBER 17, 2022

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx’ chronic kidney disease (CKD) therapy Xphozah – having rejected its marketing application in 2021 – its advisors are more confident abut the drug.

FDA 52

FDA Patients Sales Marketing 52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Non-Small Cell Lung Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Pharmaceutical Manufacturing 52

Pharmaceutical Technology

MAY 18, 2023

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmission of a new drug application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adults with chronic kidney disease on dialysis who have had insufficient response or intolerance to a phosphate binder treatment.

Food and Drug Administration 52

Food and Drug Administration FDA Physicians Food 52

pharmaphorum

AUGUST 2, 2022

It develops as a result of decompensation of other diseases of the cardiovascular system, such as hypertension, arrhythmia, cardiomyopathy, inflammatory heart diseases, etc. Therefore, dehydration therapy is an important component of the treatment of patients with heart disease. Lasix and heart disease.

Transportation 52

Transportation Patients Leads 52

Celeritas

SEPTEMBER 5, 2022

It damages the kidneys, the liver and the nervous system which leads to the weakening of the body. Leptospirosis mainly targets the kidneys and the liver, although it does also affect the blood and other organs. Leptospirosis mainly targets the kidneys and the liver, although it does also affect the blood and other organs.

Side effects 98

Side effects Consulting Medicine Doctors 98

Pharmaceutical Technology

MAY 10, 2023

The approval of Farxigain in the US not only reinforces AstraZeneca’s commitment to reducing the burden of this complex and life-threatening disease but will help patients across the full spectrum of heart failure lead healthier lives.” The latest regulatory approval was based on data obtained from the DELIVER Phase III trial.

Food and Drug Administration 52

Food and Drug Administration FDA Food Patients 52